Login
$STOK
$26.63 +$0.00 (0.0%) After hours

$STOK 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition

–Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all continuing into open-label treatment period; data readout antic...

25 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

03 Aug 2026 8-K: Other Events

We deliver this opinion with respect to certain matters in connection with the offering by Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), of the Company’s common stock, $0.0001 par value per share (the “Common Stock”),...

03 Aug 2026 8-K: Results of Operations and Financial Condition

– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027–

30 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 3, 2026, Stoke Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders, and the following proposals were adopted:

07 May 2026 8-K: Results of Operations and Financial Condition

– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome –

07 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BEDFORD, Mass., April 7, 2026 – Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zo...

27 Mar 2026 8-K: Changes in Registrant's Certifying Accountant

We were previously principal accountants for Stoke Therapeutics, Inc. and, under the date of March 16, 2026, we reported on the consolidated financial statements of Stoke Therapeutics, Inc. as of and for the years ended December 31, 2025...

03 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

26 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts (the “Lease Agre...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

05 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

04 Nov 2025 8-K: Results of Operations and Financial Condition

– Global Phase 3 EMPEROR study patient recruitment ongoing in the U.S., UK, and Japan with more than 20 patients randomized to zorevunersen or sham; Study on track to complete enrollment in second half of 2026 –

06 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Executive Employment Agreement (the “Agreement”) is made and entered into this 6th day of October, 2025 (the “Effective Date”), by and between Stoke Therapeutics, Inc. (“Stoke”), and Ian Smith (“Executive”).

12 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome –

11 Aug 2025 8-K: Regulation FD Disclosure

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

10 Jul 2025 8-K: Regulation FD Disclosure

– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 –

04 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 3, 2025, Stoke Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders, and the following proposals were adopted:

04 Jun 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK June 2025 © © COP COPY YR RI IG GH HT T 2 20 02 25 5 | | S ST TOKE OKE T TH HER ERA AP PEU EUT TI ICS CS | | 1

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support